In a report released yesterday, Matthew O’Brien from Piper Sandler reiterated a Buy rating on Minerva Surgical (UTRS – Research Report), with a price target of $5.00. The company’s shares opened today at $0.22.
According to TipRanks, O’Brien is a 4-star analyst with an average return of 2.5% and a 50.60% success rate. O’Brien covers the Healthcare sector, focusing on stocks such as Cutera, Zimmer Biomet Holdings, and CVRx.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Minerva Surgical with a $5.00 average price target.
See today’s best-performing stocks on TipRanks >>
UTRS market cap is currently $6.52M and has a P/E ratio of -0.18.
Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of UTRS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Minerva Surgical Inc is a commercial-stage medical technology company focused on developing, manufacturing, and commercializing minimally invasive solutions to meet the distinct uterine healthcare needs of women.
Read More on UTRS:
- Minerva Surgical Announces the Appointment of Kaile Zagger as Chief Commercial Officer
- Minerva Surgical Reports Fourth Quarter and Full-Year 2022 Financial Results
- Minerva Surgical to Announce Fourth Quarter and Full Year 2022 Financial Results
- Hologic announces U.S. Court of Appeals affirmation of 2021 ruling against Minerva Surgical
- Minerva Surgical Closes $30 Million Private Placement of Common Stock
